Prime Insights

    Drug Pipeline

Risdiplam approaching mid-2020 PDUFA date 

This will be the third, high cost drug treatment option emerging for spinal muscular atrophy in less than five years; many more are in the pipeline. Read more


April 2020 decisions expected from the FDA

March 13, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of April. April 2020 decisions.


Drug pipeline: February 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2020
Specialty pipeline: February 2020


March 2020 decisions expected from the FDA

February 14, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of March. March 2020 decisions.


Drug pipeline: January 2020

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2020
Specialty pipeline: January 2020


FDA issues its first approval for an oral CGRP formulation for migraine 

January 25, 2020: Ubrelvy™ brings a new treatment option (oral) to a new drug class (CGRP) for patients with migraine.  Prime stays on top of the drug pipeline so our clients don’t fall behind. Read more


Breakthrough therapy for cystic fibrosis

January 20, 2020: Trikafka’s triple combination therapy (elexacaftor/ivacaftor/tezacaftor) may cover 90% of patients with cystic fibrosis. Read more


February 2020 decisions expected from the FDA

January 17, 2020: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of February. February 2020 decisions


Quarterly drug pipelines: December 2019

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: December 2019
Specialty pipeline: December 2019


January 2020 decisions expected from the FDA

December 13, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of January. January 2020 decisions


Zyntelgo has approval in Europe

Dec. 9, 2019: Still waiting for FDA approval. Only a few thousand people worldwide might need gene therapy Zyntelgo for the most severe form of transfusion-dependent beta-thalassemia.  Zyntelgo overview


Drug pipeline: November 2019

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2019
Specialty pipeline: November 2019


December 2019 decisions expected from the FDA

December 13, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of December. December 2019 decisions


Palforzia and Viaskin Peanut getting mixed reviews

Dec. 7, 2019: Peanut avoidance may be just as effective as these peanut desensitizers. PDUFA for Palforzia expected in January 2020. Viaskin PDUFA in April 2020. Peanut desensitizer overview


Drug pipeline: October 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2019
Specialty pipeline: October 2019


November 2019 decisions expected from the FDA

Oct. 15, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of November. November 2019 decisions


New acute migraine agent – Reyvow – approved   

Oct.15, 2019: Reyvow is the first serotonin receptor agonist to target the 5-HT1F receptor. In DEA review for controlled substance classification prior to launch. Reyvow overview


Quarterly drug pipelines: September 2019

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: September 2019
Specialty pipeline: September 2019


October 2019 decisions expected from the FDA

Sept.15. 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of October. October 2019 decisions


Drug pipeline: August 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2019
Specialty pipeline: August 2019


September 2019 decisions expected from the FDA

Aug. 15, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of September. September 2019 decisions


Drug pipeline: July 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2019
Specialty pipeline: July 2019


August 2019 decisions expected from the FDA

July 15, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of August. August 2019 decisions


Quarterly drug pipelines: June 2019

These quarterly pipeline wrap-up include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: June 2019
Specialty pipeline: June 2019


New indication approved for neuromyelitis optica spectrum disorder (NMOSD)

Staying on top of the drug pipeline so our clients don’t fall behind. Soliris (eculizumab) was approved for the new indication on June 27, 2019. Soliris (eculizumab)


July 2019 decisions expected from the FDA

June 15, 2019: This synopsis looks ahead to the new drugs expecting an FDA decision in the month of July. July 2019 decisions


Drug pipeline: May 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2019
Specialty pipeline: May 2019


What does it mean now that Zolgensma is approved?

June 16, 2020: At Prime, we get ahead of drug trends to prepare for new, high-cost drugs entering the market. Zolgensma® (onasemnogene abeparvovec-xioi) was approved May 24, 2019. Zolgensma® (onasemnogene abeparvovec-xioi)


Drug pipeline: April 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2019
Specialty pipeline: April 2019


Quarterly drug pipeline: March 2019

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: March 2019
Specialty pipeline: March 2019


New drug approved for treatment-resistant depression (TRD)

June 26, 2019: Staying on top of the drug pipeline so our clients don’t fall behind. Spravato (esketamine) nasal spray was approved March 6, 2019.  Spravato (esketamine)  


Drug pipeline: February 2019

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2019
Specialty pipeline: February 2019


Drug pipeline: January 2019

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2019
Specialty pipeline: January 2019


Infographic: Rheumatoid arthritis December 2018

Dec. 2018:  44% of members newly diagnosed with RA do not start on disease modifying antirheumatic drugs (DMARDS) in their first year, as recommended by treatment guidelines. What does this mean for their treatment path? Infographic 


Quarterly drug pipeline: December 2018

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: December 2018
Specialty pipeline: December 2018


Drug pipeline: November 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2018
Specialty pipeline: November 2018


Drug pipeline: October 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2018
Specialty pipeline: October 2018


A new option opens up for severe asthma

Nov. 2018: Dupixent (dupilumab) received this FDA approval for an additional indication in 2018 as an add-on maintenance treatment for severe asthma on October 20, 2018. Dupixent (dupilumab)


Quarterly drug pipeline: September 2018

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: September 2018
Specialty pipeline: September 2018


It’s an entire new class of drugs for migraine sufferers

Oct. 2018 The new class of drugs is called selective calcitonin gene-related peptide (CGRP) antagonists for the prevention of migraine. Emgality® (galcanezumab-gnlm) is one of three CGRPs approved in 2018, on September 27, 2018.  Emgality® (galcanezumab-gnlm) 


It’s an entire new class of drugs for migraine sufferers

The new class of drugs is called selective calcitonin gene-related peptide (CGRP) antagonists for the prevention of migraine. Ajovy® (fremanezumab-vfrm) is one of three CGRPs approved in 2018, on September 14, 2018. Ajovy® (fremanezumab-vfrm) 


Drug pipeline: August 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2018
Specialty pipeline: August 2018


Drug pipeline: July 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2018
Specialty pipeline: July 2018


Quarterly drug pipeline: June 2018

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: June 2018
Specialty pipeline: June 2018


New drug treats Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS)

Epidiolex® (cannabidiol - CBD) treats two rare, drug-resistant forms of epilepsy. We’ve been following it since it began clinical trials. Epidiolex® (cannabidiol - CBD) was approved on June 27, 2018Epidiolex® (cannabidiol - CBD) 


Drug pipeline: May 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2018
Specialty pipeline: May 2018


It’s an entire new class of drugs for migraine sufferers

The new class of drugs is called selective calcitonin gene-related peptide (CGRP) antagonists for the prevention of migraine. Aimovig® (erenumab-aooe) is one of three CGRPs approved in 2018, approved on May 17, 2019. Aimovig® (erenumab-aooe) 


Drug pipeline: April 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2018
Specialty pipeline: April 2018


Quarterly drug pipeline: March 2018

These quarterly pipeline wrap-ups include includes new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

Traditional pipeline: March 2018
Specialty pipeline: March 2018


Drug pipeline: February 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2018
Specialty pipeline: February 2018


Drug pipeline: January 2018

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2018
Specialty pipeline: January 2018


Drug pipeline: December 2017

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: December 2017
Specialty pipeline: December 2017


Drug pipeline: November 2017

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2017
Specialty pipeline: November 2017


Drug pipeline: October 2017

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2017
Specialty pipeline: October 2017


Drug pipeline: September 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: September 2017
Specialty pipeline: September 2017


Drug pipeline: August 2017

This monthly pipeline wrap-up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2017
Specialty pipeline: August 2017


Drug pipeline: July 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2017
Specialty pipeline: July 2017


Drug pipeline: June 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: June 2017
Specialty pipeline: June 2017


Drug pipeline: May 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2017
Specialty pipeline: May 2017


Drug pipeline: April 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2017
Specialty pipeline: April 2017


Drug pipeline: March 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: March 2017
Specialty pipeline: March 2017


Drug pipeline: February 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2017
Specialty pipeline: February 2017


Drug pipeline: January 2017

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2017
Specialty pipeline: January 2017


Drug pipeline: December 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: December 2016
Specialty pipeline: December 2016


Drug pipeline: November 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2016
Specialty pipeline: November 2016


Nov. 11, 2016 | Prime Therapeutics

Infographic: Drug pipeline profile: Duchenne muscular dystrophy

New  therapies for this rare disease are in the pipeline, and they could have a big impact on drug costs — up to $4.57 per member per year.

DMD and what’s on the horizon


Drug pipeline: October 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2016
Specialty pipeline: October 2016


Drug pipeline: September 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: September 2016
Specialty pipeline: September 2016


Drug pipeline: August 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: August 2016
Specialty pipeline: August 2016


Drug pipeline: July 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: July 2016
Specialty pipeline: July 2016


Drug pipeline: June 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: June 2016
Specialty pipeline: June 2016


Drug pipeline: May 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: May 2016
Specialty pipeline: May 2016


Drug pipeline: April 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: April 2016
Specialty pipeline: April 2016


Drug pipeline: March 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: March 2016
Specialty pipeline: March 2016


Drug pipeline: February 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: February 2016
Specialty pipeline: February 2016


Drug pipeline: January 2016

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: January 2016
Specialty pipeline: January 2016


Drug pipeline: December 2015

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: December 2015
Specialty pipeline: December 2015


Drug pipeline: November 2015

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: November 2015
Specialty pipeline: November 2015


Drug pipeline: October 2015

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: October 2015
Specialty pipeline: October 2015


Drug pipeline: September 2015

This monthly pipeline update provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Traditional pipeline: September 2015
Specialty pipeline: September 2015